These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
89 related articles for article (PubMed ID: 11086958)
1. Introduction of the hematotoxicity modeling workshop. Krewski D; Henry C J Toxicol Environ Health A; 2000 Nov; 61(5-6):499-500. PubMed ID: 11086958 [No Abstract] [Full Text] [Related]
2. From cyclophosphamide hematotoxicity to modeling cancer. Luebeck EG J Toxicol Environ Health A; 2000 Nov; 61(5-6):515-20. PubMed ID: 11086961 [No Abstract] [Full Text] [Related]
3. A biomathematical model of cyclophosphamide hematotoxicity. Cox LA J Toxicol Environ Health A; 2000 Nov; 61(5-6):501-10. PubMed ID: 11086959 [No Abstract] [Full Text] [Related]
4. Comments on the Cox model of cyclophosphamide hematotoxicity. Krishnan K J Toxicol Environ Health A; 2000 Nov; 61(5-6):511-4. PubMed ID: 11086960 [No Abstract] [Full Text] [Related]
5. Biologically based risk assessment model for cyclophosphamide hematotoxicity in animal species: concluding comments. Andersen ME; Krewski D J Toxicol Environ Health A; 2000 Nov; 61(5-6):543-52. PubMed ID: 11086966 [No Abstract] [Full Text] [Related]
6. Comments on a biochemical model of cyclophosphamide hematotoxicity. Portier CJ; Parham FM J Toxicol Environ Health A; 2000 Nov; 61(5-6):525-8. PubMed ID: 11086963 [No Abstract] [Full Text] [Related]
7. Review of the Cox hematotoxicity model. Heaney ML; Nimer SD J Toxicol Environ Health A; 2000 Nov; 61(5-6):539-41. PubMed ID: 11086965 [No Abstract] [Full Text] [Related]
8. A clinician's comments on the cyclophosphamide hematotoxicity biologically based risk assessment model. Atkins HL J Toxicol Environ Health A; 2000 Nov; 61(5-6):529-38. PubMed ID: 11086964 [No Abstract] [Full Text] [Related]
9. Review of the Cox model. Chen C J Toxicol Environ Health A; 2000 Nov; 61(5-6):521-3. PubMed ID: 11086962 [No Abstract] [Full Text] [Related]
10. [Pharmacology of drugs impairing the hematopoietic system]. Bieroń K Przegl Lek; 1971; 28(5):378-81. PubMed ID: 5091799 [No Abstract] [Full Text] [Related]
11. An application of a marked point process in pre-clinical medicine. Berridge DM Stat Med; 1996 Dec; 15(24):2751-62. PubMed ID: 8981684 [TBL] [Abstract][Full Text] [Related]
12. [Immunologic mechanisms in states of drug-induced impairment of the hematopoietic system]. Szmigiel Z Przegl Lek; 1971; 28(5):382-4. PubMed ID: 5091800 [No Abstract] [Full Text] [Related]
13. [Experimental study on antineoplastic agents causing hematopoietic diseases]. Miyazaki S; Take H; Nagayama T Nihon Shonika Gakkai Zasshi; 1972 Jan; 76(1):38-43. PubMed ID: 4112292 [No Abstract] [Full Text] [Related]
14. [Effect of lead on the hematopoietic system with reference to environmental and occupational exposure]. Lisiewicz J; Moszczyński P Postepy Hig Med Dosw; 1986; 40(1):45-79. PubMed ID: 3532071 [No Abstract] [Full Text] [Related]
16. [Reconstitution of cyclophosphamide-induced, impaired function of the immune system in animal models]. Artym J Postepy Hig Med Dosw; 2003; 57(1):55-66. PubMed ID: 12765123 [TBL] [Abstract][Full Text] [Related]
17. Hematologic side-effects of dapsone. Wilson JR; Harris JW Ohio State Med J; 1977 Aug; 73(8):557-60. PubMed ID: 887243 [No Abstract] [Full Text] [Related]
18. Hematologic side-effects of chloramphenicol. Schröter W Neuropadiatrie; 1974 May; 5(2):117-20. PubMed ID: 4601885 [No Abstract] [Full Text] [Related]